Skip to content

Salivary microbiome dysbiosis associated with the pre-epithelial mucosa barrier impairment in laryngopharyngeal reflux

Salivary microbiome dysbiosis associated with the pre-epithelial mucosa barrier impairment in laryngopharyngeal reflux

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091947
Enrollment
Unknown
Registered
2024-11-06
Start date
2023-03-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laryngopharyngeal reflux

Interventions

Case group:None
Control group:None

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 58 Years

Inclusion criteria

Inclusion criteria: Outpatient patients who do not complain of discomfort in the throat and meet the inclusion and exclusion criteria are the control group. Case group: Outpatient patients in the Department of Otolaryngology, presenting with symptoms such as foreign body sensation in the throat, persistent clearing of the throat, hoarseness, voice fatigue, sore throat, chronic cough, and difficulty breathing. The onset time is more than 3 months, RSI>13 points, and the Dx PH monitoring result is positive for LPR patients. Inclusion criteria (1) The patient is aged between 18 and 78 years old; (2) No serious systemic or mental illnesses; (3) Sign informed consent; (4) Unbeneficial habits of consuming probiotics and prebiotics.

Exclusion criteria

Exclusion criteria: (1) Patients with diabetes, hypertension, malignant tumor, respiratory system disease, endocrine disease, heart disease, arrhythmia, cardiogenic chest pain, cerebrovascular accident, upper gastrointestinal diseases, upper abdominal surgery or other serious systemic diseases; (2) Recently used drugs that have an impact on autonomic nervous system function, such as cholinergic agonists or antagonists, adrenergic agonists or antagonists, neuromuscular blockade drugs used before anesthesia, antipsychotics, immunomodulators, and prostaglandin drugs; (3) Long term smoking or excessive drinking; (4) Drinking beverages containing caffeine and alcohol within 24 hours before the experiment, resulting in significant changes in dietary structure; (5) Women during their menstrual period, pregnant or breastfeeding period; (6) Oral antibiotics and proton pump inhibitors in the past month; (7) Patients with upper respiratory tract infections and those who have been cured within 2 weeks; (8) Individuals with acute oral infections; (9) Medications that may affect the judgment of test results need to be added midway.

Design outcomes

Primary

MeasureTime frame
Mucin in saliva;SIgA;EGF;TGF-a;Salivary inflammatory factors;Salivary microbiota;

Secondary

MeasureTime frame
Salivary secretion;Non stimulating and stimulating total saliva flow rate;Salivary pH value;Salivary buffering capacity;

Countries

China

Contacts

Public ContactZhang Yanping

Chinese PLA General Hospital

yzhan28@163.com+86 138 1043 3179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026